Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.42 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 4/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15519349 | 0.79 | ADORA2A (0.41) | ADORA2AADORA2BPIK3CDPOLBADORA3 | |
| SCHEMBL20224870 | 0.79 | MAP2K1 (0.42) | ADORA2AADORA2BPIK3CDPOLBADORA3 | |
| SCHEMBL25665415 | 0.79 | ADORA2A (0.41) | ADORA2AADORA2BPIK3CDPOLBADORA3 | |
| SCHEMBL20224896 | 0.79 | ADORA2A (0.41) | ADORA2AADORA2BPIK3CDPOLBADORA3 | |
| SCHEMBL22883502 | 0.69 | MAP2K1 (0.38) | ADORA2AADORA2BPIK3CDPOLBADORA3 | |
| SCHEMBL6935760 | 0.68 | ADORA2A (0.33) | ADORA2AADORA1NOTUMCYP1A2MAPK1 | |
| SCHEMBL12235955 | 0.68 | CDK5 (0.38) | CYP1A2 | |
| SCHEMBL21887491 | 0.68 | ADORA2A (0.38) | ADORA2AADORA2BPIK3CDPOLBADORA3 | |
| SCHEMBL15580432 | 0.68 | LMNA (0.42) | GDABCAT2LMNAHPGDCYP3A4 | |
| SCHEMBL14438644 | 0.67 | ADORA2A (0.48) | ADORA2AADORA2BPIK3CDPOLBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-2708540-B1 | PYRIMIDO-DIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO LTD (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9453021-B2 | Pyrimidodiazepinone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9453021-B2 | Pyrimidodiazepinone compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149560-A1 | LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF | STING1, CGAS, TLR9 | ADORA2A 2409/4885ADORA2B 3423/4885PIK3CD 132/4885 |
| US-20140171422-A1 | PYRIMIDODIAZEPINONE COMPOUND | REN, AGTR1, KCNJ1 | ADORA2A 795/4885ADORA2B 723/4885PIK3CD 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.